ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 512,84
0,32%
DAX
18 772,85
0,50%
Brent Oil
82,585
0,00%
Bitcoin
61 002,26
0,33%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Sema4 Holdings Corporation (SMFR)

  7. Sema4 Holdings Corporation (SMFR) Actualités

SMFR

Sema4 (SMFR)

Sema4 Holdings Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SMFR
DateHeureSourceTitreSymboleSociété
21/06/202322h07Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SMFRSema4 Holdings Corporation
20/06/202323h17Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SMFRSema4 Holdings Corporation
09/06/202322h16Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SMFRSema4 Holdings Corporation
25/04/202323h25Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:SMFRSema4 Holdings Corporation
20/04/202322h28Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SMFRSema4 Holdings Corporation
10/02/202322h06Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SMFRSema4 Holdings Corporation
01/02/202323h12Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:SMFRSema4 Holdings Corporation
30/01/202323h14Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:SMFRSema4 Holdings Corporation
09/01/202314h30GlobeNewswire Inc.Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 GuidanceNASDAQ:SMFRSema4 Holdings Corporation
30/12/202214h30GlobeNewswire Inc.Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare ConferenceNASDAQ:SMFRSema4 Holdings Corporation
05/12/202214h00GlobeNewswire Inc.New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICUNASDAQ:SMFRSema4 Holdings Corporation
14/11/202214h02GlobeNewswire Inc.Sema4 Reports Third Quarter 2022 Financial Results and New Strategic DirectionNASDAQ:SMFRSema4 Holdings Corporation
04/11/202221h05GlobeNewswire Inc.Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022NASDAQ:SMFRSema4 Holdings Corporation
04/11/202210h45PR Newswire (US)SMFR SHAREHOLDER ALERT: Jakubowitz Law Reminds Sema4 Holdings Corp. Shareholders of a Lead Plaintiff Deadline of November 7, 2022NASDAQ:SMFRSema4 Holdings Corporation
03/11/202203h50PR Newswire (US)FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Sema4 Holdings Corp. - SMFRNASDAQ:SMFRSema4 Holdings Corporation
02/11/202210h45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Sema4 Holdings, Corp. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 7, 2022 - (NASDAQ: SMFR)NASDAQ:SMFRSema4 Holdings Corporation
31/10/202214h00GlobeNewswire Inc.Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained EpilepsiesNASDAQ:SMFRSema4 Holdings Corporation
27/10/202214h00GlobeNewswire Inc.Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill NewbornsNASDAQ:SMFRSema4 Holdings Corporation
26/10/202214h00GlobeNewswire Inc.Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panelsNASDAQ:SMFRSema4 Holdings Corporation
13/10/202214h00GlobeNewswire Inc.Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum DisordersNASDAQ:SMFRSema4 Holdings Corporation
05/10/202214h00GlobeNewswire Inc.Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening StudyNASDAQ:SMFRSema4 Holdings Corporation
08/09/202212h04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SMFRSema4 Holdings Corporation
07/09/202223h26Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:SMFRSema4 Holdings Corporation
26/08/202222h56Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:SMFRSema4 Holdings Corporation
26/08/202214h00GlobeNewswire Inc.Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial OfficerNASDAQ:SMFRSema4 Holdings Corporation
18/08/202205h25TipRanksBTIG Sticks to Their Buy Rating for Sema4 Holdings (SMFR)NASDAQ:SMFRSema4 Holdings Corporation
15/08/202222h47Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SMFRSema4 Holdings Corporation
15/08/202222h05GlobeNewswire Inc.Sema4 Announces Continued Restructuring, Business Highlights, and Reports Second Quarter 2022 Financial ResultsNASDAQ:SMFRSema4 Holdings Corporation
15/08/202222h05GlobeNewswire Inc.Sema4 Announces Changes to its Research & Development LeadershipNASDAQ:SMFRSema4 Holdings Corporation
26/07/202214h00GlobeNewswire Inc.Sema4 to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022NASDAQ:SMFRSema4 Holdings Corporation
 Showing the most relevant articles for your search:NASDAQ:SMFR

Dernières Valeurs Consultées

USOTC
AHAHF
Design Milk (PK)
BINA
PLAUSDT
PlayDapp Token
LSE
MPE
M.p. Evans
LSE
106G
EU
INRTA
Lyxor RTA Inav
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés